Klinikum der Universitaet Muenchen AöR — Sponsor Intelligence | 16 EU Trials

Filter these 16 trials by condition, phase, country and more.

Open in Search →

16 Registered trials

7 Recruiting

7 Completed trials

14 Countries active

47 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III: 3 Phase II/III: 1 Phase II: 8 Phase I/II: 3 Phase IV: 1

100%

7 of 7 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Mantle cell lymphoma stage II 2 Mantle cell lymphoma stage IV 2 Mantle cell lymphoma stage III 2 Schizophrenia 1 Chronic hepatitis B 1 Myocardial infarction 1 Ischaemic stroke 1 Deep vein thrombosis 1 Crohn's disease 1

Top IMPs

BEVACIZUMAB 2 PLACEBO 2 APIXABAN 1 ATEZOLIZUMAB 1 AZACITIDINE 1 BREXUCABTAGENE AUTOLEUCEL 1 CLEMASTINE 1 DORNASE ALFA 1 DURVALUMAB 1 GLOFITAMAB 1 HEPATITIS B SURFACE ANTIGEN (RDNA) 1 IBRUTINIB 1

All trials

16 total

Reduction of SystemiC Inflammation after ischemic stroke by intravenous DNase administration (ReSCInD) Pending

2024-516701-22-00 Phase II 1 country DORNASE ALFA; SODIUM CHLORIDE
L-Thyroxine for the treatment of acute unilateral ves-tibulopathy (AUVP): a monocentric, double-blind, pla-cebo-controlled trial. Acronym: T… Pending

2024-519515-34-00 Phase II 1 country LEVOTHYROXINE SODIUM; PLACEBO
PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA Recruiting

2024-512922-27-00 Phase II 5 countries GLOFITAMAB
CAR-T-cell treatment for untreated high risk MANtle Cell Lymphoma Recruiting

2022-502405-15-01 Phase II 5 countries BREXUCABTAGENE AUTOLEUCEL; IBRUTINIB
Assessment of the safety and efficacy of a hepatitis B vaccine in adult patients with hepatitis B Recruiting

2023-507623-36-00 Phase I/II 1 country HEPATITIS B SURFACE ANTIGEN (RDNA); MOSAIC HBCOREAG; MVA-HBVAC
PROTamine Application in patients underGOing tRAnScatheter aortic valve replacement (PROTAGORAS) Recruiting

2024-512024-10-01 Phase III 1 country PROTAMINE SULFATE
EEN-RICH study Recruiting

2022-503027-10-00 Phase I/II 1 country INTESTIFIX
Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat) Recruiting

2024-514457-30-00 Phase II 1 country CLEMASTINE; PLACEBO
Study on the effect of 2 immunotherapy drugs in combination with radioactive glass spheres on the survival in liver cancer Recruiting

2024-515127-11-00 Phase II 2 countries
Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) pati… Ended

2024-511439-84-00 Phase II 2 countries BEVACIZUMAB; DURVALUMAB
A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand s… Ended

2024-512682-14-00 Phase II 1 country ATEZOLIZUMAB; BEVACIZUMAB
A multicenter, randomized, double-blind, placebo-controlled TRial evaluating Immunosuppressive treatment in patients with chronic virus-Nega… Ended

2024-512451-20-00 Phase II/III 1 country MYCOPHENOLATE MOFETIL; PREDNISOLONE
Escalated single Platelet Inhibition for one month plus Direct oral anticoagulation in patients with Atrial fibrillation and acUte coRonary … Ended

2024-512727-36-00 Phase IV 2 countries
An Open-Label Phase I/II Study of Relatlimab (BMS-986016) with Nivolumab (BMS-936558) in Combination with 5-Azacytidine for Relapsed/Refract… Ended

2024-514948-89-00 Phase I/II 1 country AZACITIDINE; NIVOLUMAB
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea… Ended

2024-511235-10-00 Phase III 12 countries
Prevention of thrombotic events in the context of long distance flights Ended

2024-515630-33-00 Phase III 1 country APIXABAN

Showing 1–16 of 16 trials

← All sponsors A–Z